Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure
Information source: Merck
Information obtained from ClinicalTrials.gov on December 31, 2007
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Heart Failure
Intervention: MK0954, losartan potassium / Duration of Treatment: 7 years (Drug)
Phase: Phase 3
Status: Active, not recruiting
Sponsored by: Merck
Summary
This is a multicenter study to evaluate potential decrease in hospitalization events and time
between events and increasing longevity in patients with symptomatic congestive heart failure
and intolerant of first-line medication for heart failure. This study will evaluate if higher
doses of the investigational drug given daily will be superior to the lower dose of the same
investigational drug given daily.
Clinical Details
Official title: A Multi-Center, Double-Blind, Randomized, Parallel Group Study to Evaluate the Effects of Two Different Doses of Losartan on Morbidity and Mortality in Patients With Symptomatic Heart Failure Intolerant of ACE Inhibitor Treatment
Study design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study
Primary outcome: Composite event rate of all cause death and/or hospitalization for heart failure
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
Symptomatic heart failure with known or recently diagnosed intolerance of treatment with
first-line medication for heart failure;
May or may not be receiving an alternative and/or additional drug treatment.
Locations and Contacts
Call for International Site Information, Horsham, Pennsylvania 19044, United States
Additional Information
Starting date: November 2001
Last updated: May 17, 2006
|
